Nicolet Advisory Services LLC Has $1.56 Million Position in Johnson & Johnson (NYSE:JNJ)

Nicolet Advisory Services LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,008 shares of the company’s stock after selling 975 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Johnson & Johnson were worth $1,564,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $32,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on JNJ shares. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday. Raymond James decreased their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Bank of America raised their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a report on Wednesday, March 5th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Stock Up 1.4 %

Shares of NYSE:JNJ opened at $155.41 on Thursday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm has a market capitalization of $374.51 billion, a P/E ratio of 23.37, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a 50 day moving average price of $159.36 and a 200-day moving average price of $155.98.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.29 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.